Beginning in mid-February 2008, the 1997-2007 online version of the Science Watch® newsletter, ESI-Topics.com, and in-cites.com, will all be featured together on the redesigned ScienceWatch.com. All previous content from the three sites will be permanently archived, and remain accessible from any existing bookmarks to the archived pages. No new content will be added to this site. Updates and new content (updated biweekly) are available at ScienceWatch.com now.

Emerging Research Fronts Comments

Return to menu of Emerging Research Fronts

ESI Special Topics, August 2004
Citing URL: http://www.esi-topics.com/erf/2004august04-MichaelZaugg.html

From •>>August 2004

Michael Zaugg answers a few questions about this month's emerging research front in field of Clinical Medicine:

Clinical Medicine
Article: Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K-ATP channels via multiple signaling pathways
Authors: Zaugg, M;Lucchinetti, E;Spahn, DR;Pasch, T;Schaub, MC
Journal: ANESTHESIOLOGY, 97: (1) 4-14, JUL 2002
Addresses:
Univ Zurich Hosp, Inst Anesthesiol, Ramistr 1000, CH-8091 Zurich, Switzerland.
Univ Zurich Hosp, Inst Anesthesiol, CH-8091 Zurich, Switzerland.Univ Lausanne Hosp, Dept Pharmacol & Toxicol, Lausanne, Switzerland.
Univ Lausanne Hosp, Dept Anesthesiol, Lausanne, Switzerland.
Univ Zurich Hosp, Inst Anesthesiol, CH-8091 Zurich, Switzerland.


ST:  Could you summarize the significance of your paper in layman's terms?


“Cardiovascular complications represent a major problem in elderly patients undergoing surgery”

The results presented in this paper unravel the basic mechanisms underlying pharmacological preconditioning (=protection against lethal ischemia) elicited by volatile anesthetics. These fundamental observations are important for clinicians as well as basic scientists interested in cardiac protection (translational research).

Volatile anesthetics may not only be used perioperatively to protect the heart of high-risk surgical patients but also may be administered in patients undergoing coronary interventions. As volatile anesthetics further induce a “second window of protection” (=protection occurring 24 hrs after the application and lasting for 3-4 days), they may be used in many clinical settings to prevent cardiovascular complications.

Volatile anesthetics are protective at subanesthetic concentrations, as demonstrated in my publication. At these concentrations, no side effects will occur.

Cardiovascular complications represent a major problem in elderly patients undergoing surgery. Since 1997, my research has focused on cardioprotective treatments such as pharmacological preconditioning to reduce perioperative cardiovascular complications.

My paper is based on the following findings:

  1. Mitochondria are the main sites of protection elicited by volatile anesthetics.

  2. The publication shows for the first time that volatile anesthetics prime or activate mitochondrial ATP-dependent potassium channels. Additional experiments show that this activation is clearly associated with significant cell protection.

  3. Multiple signaling pathways are involved in establishing the protective cellular state. These include activation of protein kinase C, nitric oxide, adenosine, and Gi-protein coupled receptors.End

Privatdozent Michael Zaugg
Institute of Anesthesiology University Hospital Zurich and
Institute of Pharmacology University Zurich
Zurich, Switzerland

Return to Emerging Research Fronts | Return to Special Topics main menu
 

ESI Special Topics, August 2004
Citing URL: http://www.esi-topics.com/erf/2004/august04-MichaelZaugg.html

ScienceWatch.com - Tracking Trends and Perfomance in Basic Research
Go to the new ScienceWatch.com

Write to the Webmaster with questions/comments. Terms of Usage.
The Research Services Group of Thomson Scientific |
(c) 2008 The Thomson Corporation.